Literature DB >> 9988185

An analysis of features of pathogenesis in two animal models of Ebola virus infection.

E I Ryabchikova1, L V Kolesnikova, S V Luchko.   

Abstract

Virus reproduction and the time course of changes in liver and kidney functions and in the blood clotting system were studied in the visceral organs of green monkeys and baboons infected with Ebola virus (subtype Zaire). It was shown that monocytes and macrophages were the first cells to be infected with the virus, followed by hepatocytes, adrenocorticocytes, fibroblasts, and endotheliocytes. The early and late pathologic changes in the monkey organs are described. Biochemical data on changes in blood clotting and liver and kidney functions in the course of the infection are presented. The responses of blood clotting and vascular permeability were species specific: Fibrin deposited in blood vessels in green monkeys, while hemorrhages developed in baboons. The results show that species-specific features of monkeys must be taken into account when choosing an experimental model for studying Ebola virus infection.

Entities:  

Mesh:

Year:  1999        PMID: 9988185     DOI: 10.1086/514293

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  73 in total

1.  Infection and activation of monocytes by Marburg and Ebola viruses.

Authors:  U Ströher; E West; H Bugany; H D Klenk; H J Schnittler; H Feldmann
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 2.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

3.  Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.

Authors:  Graham Simmons; Andrew J Rennekamp; Ning Chai; Luk H Vandenberghe; James L Riley; Paul Bates
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoprotein.

Authors:  Tetsuro Ikegami; Masahiro Niikura; Masayuki Saijo; Mary E Miranda; Alan B Calaor; Marvin Hernandez; Luz P Acosta; Daria L Manalo; Ichiro Kurane; Yasuhiro Yoshikawa; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

5.  DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus.

Authors:  Andrea Marzi; Thomas Gramberg; Graham Simmons; Peggy Möller; Andrew J Rennekamp; Mandy Krumbiegel; Martina Geier; Jutta Eisemann; Nadine Turza; Bertrand Saunier; Alexander Steinkasserer; Stephan Becker; Paul Bates; Heike Hofmann; Stefan Pöhlmann
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.

Authors:  Victoria M Wahl-Jensen; Tatiana A Afanasieva; Jochen Seebach; Ute Ströher; Heinz Feldmann; Hans-Joachim Schnittler
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 8.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

9.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.